Ruxolitinib cream for the treatment of atopic dermatitis

Atopic dermatitis (AD; also called atopic eczema) is a chronic, relapsing inflammatory skin disease that most commonly affects children but may also affect adults. Ruxolitinib cream is a topical treatment that inhibitsJanus kinase (JAK) 1 and JAK2, two enzymes that alter inflammatory pathways involved in atopic dermatitis.

In the United States, it is approved for the short-term and non-continuous long-term treatment of non-immunocompromised patients aged ≥12 years whose disease is not adequately controlled by topical prescription therapies or where these therapies are not advisable. Patients treated with ruxolitinib 1.5% cream twice daily for 8 weeks experienced clearer skin and reduced itching and sleep disturbance compared with a non-medicated cream. Additionally, when the treatment is used as needed, clearer skin is maintained for an additional 44 weeks. The safety profile of ruxolitinib 1.5% cream is similar to that of non-medicated creams, with minimal stinging/burning sensation after use. Therefore, ruxolitinib 1.5% cream offers an alternative to existing topical medications (such as corticosteroids and calcineurin inhibitors) for the treatment of mild-to-moderate atopic dermatitis in adults and adolescents.

The original drug of ruxolitinib cream has not yet been marketed in China, so it cannot be included in medical insurance. The price of ruxolitinib cream Original drug, specificationsinn 1.5%*60g, which is marketed overseas, is around RMB 20,000 per tube (the price may fluctuate due to the exchange rate), which is relatively expensive. The price of generic ruxolitinib cream marketed overseas is relatively cheap, and its pharmaceutical ingredients are basically the same as those of the original drug. The price of the specificationinn 1.5%*30g produced by a Bangladesh pharmaceutical factory is around 600 yuan per tube (the price may fluctuate due to exchange rate effects).